SONNET BIOTHERAPEUTICS HOLDI (SONN) Stock Analyst Ratings
USA - NASDAQ:SONN - US83548R4020 - Common Stock
4.94 USD
+0.5 (+11.26%)
4.95 USD
+0.01 (+0.2%)
ChartMill assigns a Buy % Consensus number of 83% to SONN. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 20.4. This target is 312.96% above the current price.
SONN was analyzed by 7 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about SONN.
In the previous month the buy percentage consensus was at a similar level.
SONN was analyzed by 7 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-04-07 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-03-28 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-12-20 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-08-23 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-05-28 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-05-16 | EF Hutton | Maintains | Buy -> Buy |
| 2024-02-15 | Chardan Capital | Maintains | Buy -> Buy |
| 2023-11-27 | Ladenburg Thalmann | Initiate | Buy |
| 2023-08-16 | Chardan Capital | Maintains | Buy -> Buy |
| 2023-06-26 | EF Hutton | Reiterate | Buy -> Buy |
| 2023-05-11 | Chardan Capital | Maintains | Buy -> Buy |
| 2023-04-19 | EF Hutton | Reiterate | Buy |
| 2023-04-19 | Chardan Capital | Maintains | Buy |
| 2023-02-15 | EF Hutton | Reiterate | Buy |
| 2022-12-19 | EF Hutton | Initiate | Buy |
| 2022-09-22 | Chardan Capital | Maintains | Buy |
| 2022-08-16 | Chardan Capital | Maintains | Buy |
| 2022-02-09 | BTIG | Maintains | Buy |
| 2021-12-20 | Chardan Capital | Maintains | Buy |
| 2021-12-16 | HC Wainwright & Co. | Initiate | Buy |
| 2021-09-15 | BTIG | Initiate | Buy |
SONNET BIOTHERAPEUTICS HOLDI / SONN FAQ
What do analysts expect the price target to be for SONNET BIOTHERAPEUTICS HOLDI (SONN)?
7 analysts have analysed SONN and the average price target is 20.4 USD. This implies a price increase of 312.96% is expected in the next year compared to the current price of 4.94.
Can you provide the consensus rating for SONNET BIOTHERAPEUTICS HOLDI stock?
The consensus rating for SONNET BIOTHERAPEUTICS HOLDI (SONN) is 82.8571 / 100 . This indicates that analysts generally have a positive outlook on the stock.